Full-Field Electroretinography, Pupillometry, and Luminance Thresholds in X-Linked Retinoschisis.


Journal

Investigative ophthalmology & visual science
ISSN: 1552-5783
Titre abrégé: Invest Ophthalmol Vis Sci
Pays: United States
ID NLM: 7703701

Informations de publication

Date de publication:
03 06 2020
Historique:
entrez: 25 6 2020
pubmed: 25 6 2020
medline: 8 1 2021
Statut: ppublish

Résumé

To evaluate the nature and extent of functional abnormality in X-linked retinoschisis (XLRS) by comparing three dark-adapted, full-field measures: the electroretinogram (ERG), pupillary light reflex (PLR), and luminance threshold. ERGs, PLRs (pupil constriction due to light stimulation), and luminance thresholds were measured from seven XLRS subjects and from 10 normally sighted, age-similar controls. ERGs and PLRs were obtained for a range of flash strengths, and these data were fit with Naka-Rushton functions to derive the maximum saturated b-wave (Vmax) and PLR (Pmax) amplitudes. Additionally, semi-saturation constants were obtained for the b-wave (σ) and PLR (s). Values of 1/σ and 1/s provide sensitivity measures. Full-field, dark-adapted luminance thresholds were measured using 465-nm and 642-nm flash stimuli. Vmax and 1/σ were significantly reduced in XLRS compared to the controls (both t ≥ 5.33, P < 0.001). In comparison, Pmax was normal in the XLRS subjects (t = 1.39, P = 0.19), but 1/s was reduced (t = 7.84, P < 0.001). Luminance thresholds for the control and XLRS groups did not differ significantly (F = 3.57, P = 0.08). Comparisons among measures indicated that pupil sensitivity was correlated with luminance threshold for the long- and short-wavelength stimuli (both, r ≥ 0.77, P ≤ 0.04). Correlations among all other measures were not statistically significant. The results indicate that the presumed bipolar cell dysfunction in XLRS, indicated by b-wave abnormalities, has complex downstream effects: Dark-adapted luminance threshold and maximum pupil responses are not significantly affected, but pupil sensitivity is reduced.

Identifiants

pubmed: 32579680
pii: 2770188
doi: 10.1167/iovs.61.6.53
pmc: PMC7416904
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

53

Subventions

Organisme : NEI NIH HHS
ID : P30 EY001792
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY029796
Pays : United States

Références

Vision Res. 2001 Dec;41(28):3931-42
pubmed: 11738458
Physiol Meas. 2007 Aug;28(8):N51-6
pubmed: 17664667
Arch Ophthalmol. 1987 Apr;105(4):513-6
pubmed: 3566604
Ophthalmology. 2009 Aug;116(8):1564-73
pubmed: 19501408
Can J Ophthalmol. 1998 Apr;33(3):149-58
pubmed: 9606571
Hum Mol Genet. 2019 Sep 15;28(18):3072-3090
pubmed: 31174210
Nature. 2005 Feb 17;433(7027):749-54
pubmed: 15716953
Invest Ophthalmol Vis Sci. 2015 Nov;56(12):7130-6
pubmed: 26529047
Vision Res. 2007 Mar;47(7):946-54
pubmed: 17320141
Invest Ophthalmol Vis Sci. 2011 Nov 29;52(12):9250-6
pubmed: 22039241
Nat Genet. 1997 Oct;17(2):164-70
pubmed: 9326935
Vision Res. 1989;29(3):263-70
pubmed: 2788958
Prog Retin Eye Res. 2012 May;31(3):195-212
pubmed: 22245536
Doc Ophthalmol. 2016 Jun;132(3):157-66
pubmed: 27033713
J Vis. 2015 Mar 18;15(3):
pubmed: 25788707
Invest Ophthalmol Vis Sci. 2011 Aug 22;52(9):6624-35
pubmed: 21743008
Ophthalmology. 2013 Jul;120(7):1454-64
pubmed: 23453514
Doc Ophthalmol. 2019 Aug;139(1):11-20
pubmed: 30927187
Doc Ophthalmol. 2019 Jun;138(3):217-227
pubmed: 30929109
Doc Ophthalmol. 2015 Feb;130(1):1-12
pubmed: 25502644
Invest Ophthalmol Vis Sci. 2019 Nov 1;60(14):4872-4881
pubmed: 31747688
Br J Ophthalmol. 2006 Jan;90(1):81-6
pubmed: 16361673
Arch Ophthalmol. 2000 Aug;118(8):1098-104
pubmed: 10922205
Ophthalmic Genet. 2005 Sep;26(3):111-7
pubmed: 16272055
Sci Rep. 2017 Mar 23;7:44987
pubmed: 28332564
Front Neurol. 2019 Feb 22;10:129
pubmed: 30853933
Br J Ophthalmol. 1995 Jul;79(7):697-702
pubmed: 7662639
J Clin Invest. 2015 Jul 1;125(7):2891-903
pubmed: 26098217
Invest Ophthalmol Vis Sci. 2016 Feb;57(2):332-7
pubmed: 26830370

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH